AIRLINK 75.70 Increased By ▲ 0.27 (0.36%)
BOP 5.13 Increased By ▲ 0.06 (1.18%)
CNERGY 4.64 Decreased By ▼ -0.11 (-2.32%)
DFML 31.35 Increased By ▲ 1.25 (4.15%)
DGKC 88.30 Decreased By ▼ -2.18 (-2.41%)
FCCL 22.60 Decreased By ▼ -0.30 (-1.31%)
FFBL 33.01 Increased By ▲ 0.06 (0.18%)
FFL 10.02 Decreased By ▼ -0.03 (-0.3%)
GGL 11.35 Increased By ▲ 0.01 (0.09%)
HBL 114.50 Increased By ▲ 1.01 (0.89%)
HUBC 137.00 Increased By ▲ 0.49 (0.36%)
HUMNL 9.50 Decreased By ▼ -0.40 (-4.04%)
KEL 4.62 Decreased By ▼ -0.04 (-0.86%)
KOSM 4.69 No Change ▼ 0.00 (0%)
MLCF 40.05 Decreased By ▼ -1.05 (-2.55%)
OGDC 136.70 Increased By ▲ 1.90 (1.41%)
PAEL 27.45 Decreased By ▼ -0.16 (-0.58%)
PIAA 24.60 Decreased By ▼ -0.87 (-3.42%)
PIBTL 6.94 Increased By ▲ 0.02 (0.29%)
PPL 124.40 Decreased By ▼ -0.05 (-0.04%)
PRL 27.59 Increased By ▲ 0.19 (0.69%)
PTC 14.20 Decreased By ▼ -0.30 (-2.07%)
SEARL 60.80 Increased By ▲ 0.60 (1%)
SNGP 71.59 Increased By ▲ 1.04 (1.47%)
SSGC 10.58 Increased By ▲ 0.02 (0.19%)
TELE 8.80 Decreased By ▼ -0.09 (-1.01%)
TPLP 11.70 Decreased By ▼ -0.08 (-0.68%)
TRG 66.59 Decreased By ▼ -1.07 (-1.58%)
UNITY 25.19 Increased By ▲ 0.02 (0.08%)
WTL 1.44 Decreased By ▼ -0.04 (-2.7%)
BR100 7,768 Increased By 43.1 (0.56%)
BR30 25,599 Decreased By -1.4 (-0.01%)
KSE100 74,252 Increased By 453 (0.61%)
KSE30 23,865 Increased By 241.3 (1.02%)

imageISLAMABAD: The clinical trial of an Ebola vaccine in Switzerland has been interrupted after some patients complained of joint pains in their hands and feet.

The trial was stopped one week early in all 59 volunteers "as a measure of precaution", the University of Geneva Hospital said, BBC News reports.

The vaccine being tested is one developed by NewLink, and recently bought by Merck.

There is currently no vaccine licensed for use to protect against Ebola. Two vaccines are currently being tested in humans in a number of countries.

The side-effects in the Geneva trial were experienced by four volunteers.

The hospital said human safety trials would resume on 5 January in up to 15 volunteers after checks had taken place to ensure the joint pain symptoms were "benign and temporary".

"They are all fine and being monitored regularly by the medical team leading the study," the hospital said.

Four trials of another Ebola vaccine developed by GlaxoSmithKline, in collaboration with the United States National Institute of Allergy and Infectious Diseases, are also underway

Copyright APP (Associated Press of Pakistan), 2014

Comments

Comments are closed.